Compare Kingsoft Cloud Holdings Limited (KC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kingsoft Cloud Holdings Limited vs TG Therapeutics Inc — how do they compare? Kingsoft Cloud Holdings Limited trades at $11.72 (market cap $3.53B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 2.2× Kingsoft Cloud Holdings Limited's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Kingsoft Cloud Holdings Limited nearer its low. Which is the better fit depends on your goals.
| KC | TGTX | |
|---|---|---|
Market Cap | $3.53B | $7.64B |
Sector | Technology | Health |
52-Week High | $18.21 | $59.06 |
52-Week Low | $8.58 | $26.94 |
Enterprise Value | $3.84B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kingsoft Cloud (KC) trades at $11.75, down 1.76% today, with a bullish technical signal supported by moving averages. The company shows strong revenue growth trends (37% YoY in Q1 2026) and has beaten EPS estimates for three consecutive quarters, though it remains unprofitable with a -9.39% net margin. Recent news highlights AI-driven growth momentum, with AI cloud billing now exceeding half of public cloud revenue.
The outlook is cautiously optimistic with 70% analyst buy ratings, but profitability challenges and significant capital expenditures pose risks. The stock's valuation appears reasonable with P/S of 2.22, though negative ROE and ROA indicate operational inefficiencies that need addressing for sustained growth.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
